Penumbra, Inc. (PEN) is a publicly traded Healthcare sector company. As of May 20, 2026, PEN trades at $327.39 with a market cap of $12.84B and a P/E ratio of 74.72. PEN moved +0.24% today. Year to date, PEN is +3.93%; over the trailing twelve months it is +16.45%. Its 52-week range spans $186.97 to $362.41. Analyst consensus is neutral with an average price target of $353.00. Rallies surfaces PEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Penumbra Q1 Revenue Climbs 15.6% to $374.8M, EPS Misses Estimates: Penumbra posted Q1 net income of $32.6 million and EPS of $0.82, missing analyst projections of $1.11 per share. Revenue rose 15.6% to $374.8 million, gross margin improved 1.0 point to 67.6%, while guidance was withdrawn due to pending Boston Scientific acquisition.
| Metric | Value |
|---|---|
| Price | $327.39 |
| Market Cap | $12.84B |
| P/E Ratio | 74.72 |
| EPS | $4.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $362.41 |
| 52-Week Low | $186.97 |
| Volume | 367.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.45B |
| Net Income | $171.05M |
| Gross Margin | 67.39% |
5 analysts cover PEN: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $353.00.